APA (7th ed.) Citation

RM, C., V, W., DM, H., P, G., EP, M., JJ, W., . . . KT, F. (2024). Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(7), 1273. https://doi.org/10.1158/1078-0432.CCR-23-0633

Chicago Style (17th ed.) Citation

RM, Connolly, et al. "Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 30, no. 7 (2024): 1273. https://doi.org/10.1158/1078-0432.CCR-23-0633.

MLA (9th ed.) Citation

RM, Connolly, et al. "Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 30, no. 7, 2024, p. 1273, https://doi.org/10.1158/1078-0432.CCR-23-0633.